287 related articles for article (PubMed ID: 34425907)
1. Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas.
Wei X; Meel MH; Breur M; Bugiani M; Hulleman E; Phoenix TN
Acta Neuropathol Commun; 2021 Aug; 9(1):142. PubMed ID: 34425907
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas.
Kambhampati M; Panditharatna E; Yadavilli S; Saoud K; Lee S; Eze A; Almira-Suarez MI; Hancock L; Bonner ER; Gittens J; Stampar M; Gaonkar K; Resnick AC; Kline C; Ho CY; Waanders AJ; Georgescu MM; Rance NE; Kim Y; Johnson C; Rood BR; Kilburn LB; Hwang EI; Mueller S; Packer RJ; Bornhorst M; Nazarian J
Sci Rep; 2020 Jul; 10(1):10954. PubMed ID: 32616776
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
[TBL] [Abstract][Full Text] [Related]
6. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
[TBL] [Abstract][Full Text] [Related]
7. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Messinger D; Harris MK; Cummings JR; Thomas C; Yang T; Sweha SR; Woo R; Siddaway R; Burkert M; Stallard S; Qin T; Mullan B; Siada R; Ravindran R; Niculcea M; Dowling AR; Bradin J; Ginn KF; Gener MAH; Dorris K; Vitanza NA; Schmidt SV; Spitzer J; Li J; Filbin MG; Cao X; Castro MG; Lowenstein PR; Mody R; Chinnaiyan A; Desprez PY; McAllister S; Dun MD; Hawkins C; Waszak SM; Venneti S; Koschmann C; Yadav VN
Neuro Oncol; 2023 Jan; 25(1):54-67. PubMed ID: 35605606
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive profiling of stem-like features in pediatric glioma cell cultures and their relation to the subventricular zone.
Da-Veiga MA; Coppieters N; Lombard A; Rogister B; Neirinckx V; Piette C
Acta Neuropathol Commun; 2023 Jun; 11(1):96. PubMed ID: 37328883
[TBL] [Abstract][Full Text] [Related]
10. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
11. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
12. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
[TBL] [Abstract][Full Text] [Related]
13. Glioma-induced remodeling of the neurovascular unit.
Lee J; Lund-Smith C; Borboa A; Gonzalez AM; Baird A; Eliceiri BP
Brain Res; 2009 Sep; 1288():125-34. PubMed ID: 19595677
[TBL] [Abstract][Full Text] [Related]
14. Targeting diffuse midline gliomas: The promise of focused ultrasound-mediated blood-brain barrier opening.
Martinez PJ; Green AL; Borden MA
J Control Release; 2024 Jan; 365():412-421. PubMed ID: 38000663
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
16. Preclinical therapeutic targets in diffuse midline glioma.
Meel MH; Kaspers GJL; Hulleman E
Drug Resist Updat; 2019 May; 44():15-25. PubMed ID: 31202081
[TBL] [Abstract][Full Text] [Related]
17. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
18. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
19. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
20. In vivo measurement of glioma-induced vascular permeability.
Lee J; Baird A; Eliceiri BP
Methods Mol Biol; 2011; 763():417-22. PubMed ID: 21874468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
